CN116917339A - 靶向dr4和/或dr5的多肽以及相关组合物和方法 - Google Patents

靶向dr4和/或dr5的多肽以及相关组合物和方法 Download PDF

Info

Publication number
CN116917339A
CN116917339A CN202180087906.XA CN202180087906A CN116917339A CN 116917339 A CN116917339 A CN 116917339A CN 202180087906 A CN202180087906 A CN 202180087906A CN 116917339 A CN116917339 A CN 116917339A
Authority
CN
China
Prior art keywords
nanocage
fusion protein
monomer
fragment
subunit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180087906.XA
Other languages
English (en)
Chinese (zh)
Inventor
J-P·朱利安
E·鲁哈斯迭斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children HSC
Original Assignee
Hospital for Sick Children HSC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospital for Sick Children HSC filed Critical Hospital for Sick Children HSC
Publication of CN116917339A publication Critical patent/CN116917339A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180087906.XA 2020-11-25 2021-11-25 靶向dr4和/或dr5的多肽以及相关组合物和方法 Pending CN116917339A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063118306P 2020-11-25 2020-11-25
US63/118,306 2020-11-25
PCT/CA2021/051690 WO2022109743A1 (en) 2020-11-25 2021-11-25 Polypeptides targeting dr4 and/or dr5 and related compositions and methods

Publications (1)

Publication Number Publication Date
CN116917339A true CN116917339A (zh) 2023-10-20

Family

ID=81753696

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180087906.XA Pending CN116917339A (zh) 2020-11-25 2021-11-25 靶向dr4和/或dr5的多肽以及相关组合物和方法

Country Status (9)

Country Link
US (1) US20240182544A1 (https=)
EP (1) EP4251654A4 (https=)
JP (1) JP2023550191A (https=)
KR (1) KR20230116833A (https=)
CN (1) CN116917339A (https=)
AU (1) AU2021386892A1 (https=)
CA (1) CA3202378A1 (https=)
MX (1) MX2023006148A (https=)
WO (1) WO2022109743A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240101550A9 (ko) * 2021-09-13 2025-12-10 더 호스피탈 포 식 칠드런 암 치료용 dr5-표적화 다중체
KR20250135167A (ko) * 2022-09-11 2025-09-12 래디언트 바이오테라퓨틱스 인크. 다중체를 사용하는 화학요법-내성 종양의 치료

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109195626B (zh) * 2015-10-30 2022-09-13 银河生物技术有限责任公司 结合死亡受体4和死亡受体5的抗体
WO2019023811A1 (en) * 2017-08-04 2019-02-07 The Hospital For Sick Children NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY
JP2022529512A (ja) * 2019-04-25 2022-06-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗体で修飾した自己集合するタンパク質ナノケージ（ｓａｐｎａ）及びその部分

Also Published As

Publication number Publication date
CA3202378A1 (en) 2022-06-02
AU2021386892A1 (en) 2023-06-22
JP2023550191A (ja) 2023-11-30
AU2021386892A9 (en) 2024-08-08
EP4251654A1 (en) 2023-10-04
MX2023006148A (es) 2023-08-07
US20240182544A1 (en) 2024-06-06
WO2022109743A1 (en) 2022-06-02
KR20230116833A (ko) 2023-08-04
EP4251654A4 (en) 2024-11-27

Similar Documents

Publication Publication Date Title
JP7254519B2 (ja) Ｔ細胞レセプター
JP7068231B2 (ja) ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法
CN113728005B (zh) Cd3特异性结合分子
TWI585104B (zh) 基於vl和vhh可變區衍生物的高親和力抗聚集抗體
KR20220107151A (ko) 다가 및 다중특이적 나노입자 플랫폼 및 방법
CN112409480B (zh) 结合血清白蛋白的蛋白及其用途
JP7089806B2 (ja) 悪性ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途
KR20230136166A (ko) 멀타바디 구축물, 조성물, 및 방법
JP7818828B2 (ja) 特異的結合分子
US20230167185A1 (en) Cd40 binding protein
US20250326800A1 (en) Novel polypeptides
KR20230083316A (ko) Sars-cov-2를 표적화하는 폴리펩티드, 및 관련 조성물 및 방법
CN116917339A (zh) 靶向dr4和/或dr5的多肽以及相关组合物和方法
JP2023532760A (ja) 特異的結合分子
JP2023546269A (ja) Ｔ細胞を増殖させるための二重特異性コンストラクトおよび関連する方法
JP2025534309A (ja) 多価タンパク質およびスクリーニング法
RU2859397C2 (ru) МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ IL27Rα, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN116615255A (zh) 靶向SARS-CoV-2的多肽及相关组合物和方法
HK40093836A (zh) 白细胞介素2突变体以及含有其的复合物
CN117915950A (zh) 一种多特异性抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination